



## **Prior Authorization Request Form for Sedative Hypnotics**

## FAX this completed form to (877) 386-4695

0

<u>OR</u> Mail requests to: Envolve Pharmacy S	Solutions PA Departme	nt   5 River F	Park Place East, Suite 210   Fresno, CA 9372
I. PROVIDER INFORMATION	II. MEMBER INFO	RMATION	
Prescriber Name:	Member Name:	Member Name:	
Prescriber Specialty:	Identification #:		
Office Contact Name:	Group #:		
Group Name:	me: Date of Birth:		
Fax #:	Medication Allergies:		
Phone #:			
III. DRUG INFORMATION (One drug	request per form)		
Drug name and strength:	Oosage Interval (sig):		Qty. per Day:
IV. REQUIRED DOCUMENTION (Details item must be submitted with prior at			ion demonstrating evidence for each
Specify diagnosis & diagnosis code relevant	to this request:	Dx/Dx Code:	
For Controlled Substances: Did the prescriber or prescriber's delegate search the Pennsylvania Prescription Drug Monitoring Program (PDMP) to review the member's controlled substance prescription history before issuing this prescription for the requested agent?		☐ Yes	Submit documentation.
<b>Requests for all non-preferred Sedative Hypnotics</b> : Does the member have a history of trial and failure of or contraindication or intolerance to the preferred Sedative Hypnotics? <i>Refer to</i> <a href="https://papdl.com/preferred-drug-list">https://papdl.com/preferred-drug-list</a> for a list of preferred and non-preferred medications in this class.		□ Yes	Submit documentation of previous trials/failures, contraindications, and/or intolerances.
CHECK ALL THAT APPLY. SUBMIT MEDIT Therapeutic Duplication:	nzodiazepine, one of the rom another benzodiaze itant use of benzodiaze terature criptions for any benzo consistent with medical eviewed medical literatu bed by the same prescribed by different prescribed other benzodiazepiceeding daily limit (Referent prescribeeding daily limit (Referent prescribereding	following: epine pines is suppodiazepine in telly accepted pine or national liber bers ne prescription	orted by national treatment guidelines or the past 30 days, both of the following: rescribing practices and standard of care, altreatment guidelines
UNDER 21 YEARS OR AGE:  ☐ Member has one of the following di ☐ Seizure Disorder ☐ Chemotherapy Induced Nause ☐ Cerebral Palsy		t apply:	

☐ Spastic Disorder				
☐ Dystonia				
☐ Catatonia				
☐ Receiving Palliative Care				
NON-24 HOUR SLEEP-WAKE DISORDER:				
☐ Both of the following:				
☐ Is totally blind (has no light perception)				
One of the following:				
Documented history of therapeutic failure of a 6-month trial of melatonin				
Documented instory of therapeutic failure of a o-month trial of meratorini  Documented contraindication or intolerance to melatonin				
NON-PREFERRED SEATIVE HYPNOTIC:				
Both of the following:				
<del>-</del>				
FDA approved or medically accepted indication				
Documented history of therapeutic failure, contraindication or intolerance to the preferred Sedative Hypnotic (medication, start and end date):				
NON-PREFERRED CONTROLLED-RELEASE SEATIVE HYPNOTIC:				
Documented history of therapeutic failure of the same regular-release Sedative Hypn	otic (medication, start and end			
date):				
CONCURRENTLY USE OF BUPRENORPHINE AGENT FOR OPIOID DISORDER:				
The prescriptions were prescribed by the same prescriber				
☐ The prescriptions were prescribed by different prescribers				
☐ All prescribers are aware of the other benzodiazepine prescription				
☐ Has an acute need for the request Sedative Hypnotic controlled substance-specify:				
RENEWAL REQUEST:				
☐ Documentation of tolerability and a positive clinical response to the				
medication:				
IV. ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFORMAT	CION:			
Appropriate clinical information to support   Provider Signature:	Date:			
the realiest on the hasis of medical necessity	Date.			
the request on the basis of medical necessity must be submitted.	Date.			

Envolve Pharmacy Solutions will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)